Cargando…
SUN-416 Ipilimumab Associated Hypophysitis and Thyroiditis
INTRODUCTION Ipilimumab, an anti cytotoxic T lymphocyte associated antigen 4 (CTLA 4) antibody, is approved for use in advanced melanoma based upon survival benefit. Anti CTLA 4 antibodies are associated with a myriad of side effects. CLINICAL CASE A 65 year old male with stage 3A malignant melanoma...
Autores principales: | Kazi, Fatima, Khan, Muhammad, Adhikari, Sujeen, Chadaga, Amar, Yasmeen, Tahira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552704/ http://dx.doi.org/10.1210/js.2019-SUN-416 |
Ejemplares similares
-
SUN-286 Lymphocytic Hypophysitis Mimicking Tolosa Hunt Syndrome
por: Del Castillo, Ma Dolores, et al.
Publicado: (2020) -
SUN-298 Spectrum of Imaging in Immune Checkpoint Inhibitor Induced Hypophysitis
por: Quandt, Zoe, et al.
Publicado: (2020) -
SUN-273 A Rare Case of IgG4-Related Hypophysitis
por: Ravindra, Sindhura, et al.
Publicado: (2020) -
FRI331 Autoimmune Hypophysitis Secondary To Ipilimumab And Nivolumab Combination Therapy In A Patient With Advanced Renal Cell Carcinoma
por: Ibrahim, Eiman Y, et al.
Publicado: (2023) -
SUN-441 Clinical Presentation And Diagnosis Of Primary Hypophysitis In Pediatric Age, Regarding A Case.
por: Miranda, Gonzalo
Publicado: (2019)